Infections during mobilizing chemotherapy and following autologous stem cell transplantation.
Publication/Presentation Date
12-1-2001
Abstract
Autologous peripheral blood stem cells (PBSC), for transplantation following high-dose chemotherapy, are collected using regimens containing cytokines with or without chemotherapy. The added period of neutropenia prior to stem cell transplantation (SCT) in patients receiving chemotherapy mobilization may increase the risk of infections following transplantation. We studied the incidence of culture-positive infections in 107 consecutive patients who were divided into three groups, according to whether they experienced extended neutropenia during chemotherapy for stem cell mobilization as well as post autotransplant. All the patients received antibiotic prophylaxis and hematopoietic growth factors during neutropenia. The total duration of pre-transplant neutropenia differed among the three mobilization schemes (growth factors alone; one cycle; or two cycles of chemotherapy plus growth factor for mobilization) at 0, 6 and 18 days, respectively (median). However the post-autograft time to myeloid engraftment was similar at 10 days (median). The incidence of culture-proven infections in all three groups was similar. Using fluconazole for yeast prophylaxis, 40% patients developed gastrointestinal colonization with yeast, and the majority of speciated isolates were Candida glabrata. Bacteremia developed in 22% and 9% of patients with S. epidermidis and Gram-negative organisms, respectively, while 11% developed C. difficile-associated diarrhea. In conclusion, treatment using none, one or two cycles of mobilizing chemotherapy pre-transplant does not influence the overall incidence of infections among autologous SCT recipients. However, although post-transplant neutropenia is brief, infections remain a significant cause of morbidity.
Volume
28
Issue
12
First Page
1129
Last Page
1134
ISSN
0268-3369
Published In/Presented At
Toor, A. A., van Burik, J. A., & Weisdorf, D. J. (2001). Infections during mobilizing chemotherapy and following autologous stem cell transplantation. Bone marrow transplantation, 28(12), 1129–1134. https://doi.org/10.1038/sj.bmt.1703307
Disciplines
Medicine and Health Sciences
PubMedID
11803354
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article